Genzyme has received approval from the European Commission to market Mozobil (plerixafor injection), a new treatment for patients with the blood cancers lymphoma and multiple myeloma who require an autologous stem cell transplant.

Mozobil, used in combination with granulocyte-colony stimulating factor, is designed to release haematopoietic stem cells from the bone marrow into the bloodstream where they can be collected.

This improves the chances of patients with certain types of cancers of proceeding to autologous transplant.

Genzyme vice-president and general manager Paula Soteropoulos said that there is strong interest among European physicians for Mozobil.

“With today’s approval, we will move quickly to make this important product broadly available to the transplant community,” Soteropoulos said.

The company has predicted that Mozobil will be used in the majority of procedures and has set projected peak sales at $400m annually.

Genzyme has also filed applications for the approval of Mozobil in Argentina, Australia, Brazil, Israel and Singapore.